Amber Bradley Clemmons
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Amber Bradley Clemmons has a total of 114 co-authors. Here are the top co-authors by number of shared publications:
David L DeRemer
Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Gainesville, FL, USA
3 shared publicationsAndrea Clarke
Wellstar MCG Hlth, Athens, GA USA
2 shared publications- David L. DeRemer
Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Gainesville, FL, USA
2 shared publications Jennifer L. Waller
Department of Population Health Sciences, Division of Biostatistics and Data Science, Augusta University, Augusta, USA
2 shared publicationsJeremy Pantin
Georgia Cancer Center, Augusta, Georgia; Department of Medicine, Division of Hematology and Medical Oncology, Augusta University Medical Center, Augusta, Georgia
2 shared publicationsJulianne Orr
Department of Pharmacy, Indiana University, Indianapolis, Indiana
2 shared publications
Latest Publications
- 22 February 2025
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 33 (3) , 1-6
Incidence of engraftment syndrome with and without budesonide prophylaxis in patients with multiple myeloma undergoing autologous stem cell transplant
Purpose Engraftment syndrome (ES), a rare post-transplant complication, has been defined differently across the literature. This study aims to determine if budesonide prophylaxis reduces ES after autologous hematopoietic cell transplantation (auto-HCT) for patients with multiple myeloma (MM), as defined by the published Spitzer or Maiolino criteria or by the ES definition used by Dhakal et al. Methods A single-center retrospective review was conducted on adult patients who received auto-HCT for MM between January 2017 and October 2023. Patients were divided into those who did not receive budesonide prophylaxis (n = 169) versus those who did (n = 144). The primary endpoint was an incidence of ES by the definition used by Spitzer, Maiolino, and Dhakal et al., respectively. Secondary endpoints included receipt of steroids to treat ES, hospital length of stay, engraftment, and 30- and 100-day mortality rates. Exploratory endpoints were antibiotics started in the peri-engraftment period and number of anti-diarrheal and anti-emetic doses. Results No difference existed between groups in the primary outcome by the ES definition used by Spitzer, Maiolino, or Dhakal et al. (all p > 0.05). Further, no difference existed with respect to any secondary outcomes (all p > 0.05) except a lower incidence of receipt of antibiotics in the peri-engraftment period for those who received budesonide. Conclusion Our findings suggest concordance between Spitzer and Maiolino criteria with clinically documented ES, with higher incidences when the ES definition used by Dhakal et al. is utilized. Larger controlled trials need to be performed to validate these findings.
- 22 February 2025
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 33 (3) , 1-6
Incidence of engraftment syndrome with and without budesonide prophylaxis in patients with multiple myeloma undergoing autologous stem cell transplant
Purpose Engraftment syndrome (ES), a rare post-transplant complication, has been defined differently across the literature. This study aims to determine if budesonide prophylaxis reduces ES after autologous hematopoietic cell transplantation (auto-HCT) for patients with multiple myeloma (MM), as defined by the published Spitzer or Maiolino criteria or by the ES definition used by Dhakal et al. Methods A single-center retrospective review was conducted on adult patients who received auto-HCT for MM between January 2017 and October 2023. Patients were divided into those who did not receive budesonide prophylaxis (n = 169) versus those who did (n = 144). The primary endpoint was an incidence of ES by the definition used by Spitzer, Maiolino, and Dhakal et al., respectively. Secondary endpoints included receipt of steroids to treat ES, hospital length of stay, engraftment, and 30- and 100-day mortality rates. Exploratory endpoints were antibiotics started in the peri-engraftment period and number of anti-diarrheal and anti-emetic doses. Results No difference existed between groups in the primary outcome by the ES definition used by Spitzer, Maiolino, or Dhakal et al. (all p > 0.05). Further, no difference existed with respect to any secondary outcomes (all p > 0.05) except a lower incidence of receipt of antibiotics in the peri-engraftment period for those who received budesonide. Conclusion Our findings suggest concordance between Spitzer and Maiolino criteria with clinically documented ES, with higher incidences when the ES definition used by Dhakal et al. is utilized. Larger controlled trials need to be performed to validate these findings.
- 7 October 2023
- Published by Elsevier in American Journal of Pharmaceutical Education
- Vol. 88 (1) , 100599
Translating Clinical Decision-Making Skills From a Critical Care Pharmacy Elective to the Required Curriculum
- 7 October 2023
- Published by Elsevier in American Journal of Pharmaceutical Education
- Vol. 88 (1) , 100599
Translating Clinical Decision-Making Skills From a Critical Care Pharmacy Elective to the Required Curriculum
- 27 December 2021
- Published by Elsevier in Currents in Pharmacy Teaching and Learning
- Vol. 14 (2) , 145-152
Impact of the COVID-19 pandemic on faculty at research-intensive United States schools/colleges of pharmacy
- 27 December 2021
- Published by Elsevier in Currents in Pharmacy Teaching and Learning
- Vol. 14 (2) , 145-152
Impact of the COVID-19 pandemic on faculty at research-intensive United States schools/colleges of pharmacy
- Open Access
- 1 November 2021
- Published by Harborside Press, LLC in Journal of the Advanced Practitioner in Oncology
- Vol. 12 (8) , 810-832
Premedications for Cancer Therapies: A Primer for the Hematology/Oncology Provider
Chemotherapeutic agents and radiation therapy are associated with numerous potential adverse events (AEs). Many of these common AEs, namely chemotherapy- or radiation-induced nausea and vomiting, hypersensitivity reactions, and edema, can lead to deleterious outcomes (such as treatment nonadherence or cessation, or poor clinical outcomes) if not prevented appropriately. The occurrence and severity of these AEs can be prevented with the correct prescribing of prophylactic medications, often called “premedications.” The advanced practitioner in hematology/oncology should have a good understanding of which chemotherapeutic agents are known to place patients at risk for these adverse events as well as be able to determine appropriate prophylactic medications to employ in the prevention of these adverse events. While several guidelines and literature exist regarding best practices for prophylaxis strategies, differences among guidelines and quality of data should be explored in order to accurately implement patient-specific recommendations. Herein, we review the existing literature for prophylaxis and summarize best practices.
- 1 November 2021
- Published by Harborside Press, LLC in Journal of the Advanced Practitioner in Oncology
- Vol. 12 (8) , 810-832
Open AccessPremedications for Cancer Therapies: A Primer for the Hematology/Oncology Provider
Chemotherapeutic agents and radiation therapy are associated with numerous potential adverse events (AEs). Many of these common AEs, namely chemotherapy- or radiation-induced nausea and vomiting, hypersensitivity reactions, and edema, can lead to deleterious outcomes (such as treatment nonadherence or cessation, or poor clinical outcomes) if not prevented appropriately. The occurrence and severity of these AEs can be prevented with the correct prescribing of prophylactic medications, often called “premedications.” The advanced practitioner in hematology/oncology should have a good understanding of which chemotherapeutic agents are known to place patients at risk for these adverse events as well as be able to determine appropriate prophylactic medications to employ in the prevention of these adverse events. While several guidelines and literature exist regarding best practices for prophylaxis strategies, differences among guidelines and quality of data should be explored in order to accurately implement patient-specific recommendations. Herein, we review the existing literature for prophylaxis and summarize best practices.
- 1 October 2021
- Published by Elsevier in Diagnostic Microbiology and Infectious Disease
- Vol. 101 (2) , 115444
Incidence and utility of follow-up blood cultures in cancer patients with gram-negative bacteremia
- 1 October 2021
- Published by Elsevier in Diagnostic Microbiology and Infectious Disease
- Vol. 101 (2) , 115444
Incidence and utility of follow-up blood cultures in cancer patients with gram-negative bacteremia
- 28 July 2020
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 29 (3) , 1527-1534
Assessing the impact of adding acetazolamide to oral or intravenous sodium bicarbonate as compared with intravenous bicarbonate monotherapy as urinary alkalinization in adults receiving high-dose methotrexate
Purpose High-dose methotrexate (HD-MTX) requires urine alkalinization to pH ≥ 7 for adequate excretion to prevent toxicity. Due to shortages of IV sodium bicarbonate (IV-NaHCO3), few reports have demonstrated utility of oral bicarbonate (PO-NaHCO3); however, the addition of acetazolamide (Acet) has not been well described. Our study compares outcomes between alkalinization methods of IV-NaHCO3 monotherapy versus IV-NaHCO2 + Acet and PO-NaHCO3 + Acet. Methods A single-center, IRB exempt, retrospective review was conducted from Jan 2016 to Sept 2019 of adults receiving HD-MTX ≥ 500 mg/m2. The primary outcome was time from start of alkalinization to pH ≥ 7. Secondary outcomes included time from start of alkalinization to initiation of HD-MTX, time to MTX clearance, length of stay (LOS), percentage of urine pH assessments < 7, and incidence of MTX toxicity. Statistical analysis was performed using SAS9.4 with alpha 0.05. Results Overall demographics (n = 196 HD-MTX cycles for 55 patients) include a mean age 55 years, HD-MTX dose ~ 5400 mg/m2, and 69% with a diagnosis of lymphoma. Adjusting for baseline demographic differences among groups, median time from first dose alkalinization to pH ≥ 7 and to start of HD-MTX was longer for those receiving IV-NaHCO3 (n = 41) vs either IV-NaHCO3 + Acet (n = 70) or PO-NaHCO3 + Acet (n = 76) (p = 0.0001). HD-MTX clearance to a level < 0.1 μmol/L was not improved with the addition of Acet. No difference existed among groups for pH results < 7, LOS, or incidence of MTX toxicity (p > 0.05). Conclusions Addition of Acet to NaHCO3 reduces time to pH ≥ 7 and initiation of HD-MTX but does not appear to improve LOS, MTX toxicities, or time to MTX clearance.
- 28 July 2020
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 29 (3) , 1527-1534
Assessing the impact of adding acetazolamide to oral or intravenous sodium bicarbonate as compared with intravenous bicarbonate monotherapy as urinary alkalinization in adults receiving high-dose methotrexate
Purpose High-dose methotrexate (HD-MTX) requires urine alkalinization to pH ≥ 7 for adequate excretion to prevent toxicity. Due to shortages of IV sodium bicarbonate (IV-NaHCO3), few reports have demonstrated utility of oral bicarbonate (PO-NaHCO3); however, the addition of acetazolamide (Acet) has not been well described. Our study compares outcomes between alkalinization methods of IV-NaHCO3 monotherapy versus IV-NaHCO2 + Acet and PO-NaHCO3 + Acet. Methods A single-center, IRB exempt, retrospective review was conducted from Jan 2016 to Sept 2019 of adults receiving HD-MTX ≥ 500 mg/m2. The primary outcome was time from start of alkalinization to pH ≥ 7. Secondary outcomes included time from start of alkalinization to initiation of HD-MTX, time to MTX clearance, length of stay (LOS), percentage of urine pH assessments < 7, and incidence of MTX toxicity. Statistical analysis was performed using SAS9.4 with alpha 0.05. Results Overall demographics (n = 196 HD-MTX cycles for 55 patients) include a mean age 55 years, HD-MTX dose ~ 5400 mg/m2, and 69% with a diagnosis of lymphoma. Adjusting for baseline demographic differences among groups, median time from first dose alkalinization to pH ≥ 7 and to start of HD-MTX was longer for those receiving IV-NaHCO3 (n = 41) vs either IV-NaHCO3 + Acet (n = 70) or PO-NaHCO3 + Acet (n = 76) (p = 0.0001). HD-MTX clearance to a level < 0.1 μmol/L was not improved with the addition of Acet. No difference existed among groups for pH results < 7, LOS, or incidence of MTX toxicity (p > 0.05). Conclusions Addition of Acet to NaHCO3 reduces time to pH ≥ 7 and initiation of HD-MTX but does not appear to improve LOS, MTX toxicities, or time to MTX clearance.
- Open Access
- 2 January 2020
- Published by SAGE Publications in Hospital Pharmacy
- Vol. 55 (2) , 84
Reply to: Intravenous Magnesium Replacement in Patients With Hypomagnesemia: Time Is of the Essence
- 2 January 2020
- Published by SAGE Publications in Hospital Pharmacy
- Vol. 55 (2) , 84
Open AccessReply to: Intravenous Magnesium Replacement in Patients With Hypomagnesemia: Time Is of the Essence
- Open Access
The Hematopoietic Cell Transplant Pharmacist: A Call to Action
Recently, the required training and credentials for as well as the various roles of the hematopoietic cell transplant (HCT) pharmacist have been endorsed by the leading organizations in cellular therapy, the American Society of Transplant and Cellular Therapy and the European Society of Blood and Bone Marrow Transplantation. While these documents establish the roles a HCT pharmacist can fulfill within the multi-disciplinary team, few reports have evaluated the impact of the HCT pharmacist on clinical, financial, or quality outcomes. Further, a paucity of information has been reported on types of practice models, such as the use of collaborative practice agreements, or described effective methods to overcome the barriers to the increased utilization of HCT pharmacists. Herein, a brief summary of available information is provided to aid readers in understanding the state of the science for pharmacists practicing in this specialty with the goal to stimulate further research to justify the roles of HCT pharmacists and the correlation of such research to various outcome measures. Practitioners are encouraged to build upon this existing knowledge to create the novel integration and elevation of pharmacy practice to improve outcomes for patients, providers, and payors.
Open AccessThe Hematopoietic Cell Transplant Pharmacist: A Call to Action
Recently, the required training and credentials for as well as the various roles of the hematopoietic cell transplant (HCT) pharmacist have been endorsed by the leading organizations in cellular therapy, the American Society of Transplant and Cellular Therapy and the European Society of Blood and Bone Marrow Transplantation. While these documents establish the roles a HCT pharmacist can fulfill within the multi-disciplinary team, few reports have evaluated the impact of the HCT pharmacist on clinical, financial, or quality outcomes. Further, a paucity of information has been reported on types of practice models, such as the use of collaborative practice agreements, or described effective methods to overcome the barriers to the increased utilization of HCT pharmacists. Herein, a brief summary of available information is provided to aid readers in understanding the state of the science for pharmacists practicing in this specialty with the goal to stimulate further research to justify the roles of HCT pharmacists and the correlation of such research to various outcome measures. Practitioners are encouraged to build upon this existing knowledge to create the novel integration and elevation of pharmacy practice to improve outcomes for patients, providers, and payors.
- 1 October 2019
- Published by Harborside Press, LLC in Journal of the Advanced Practitioner in Oncology
- Vol. 10 (7) , 730-735
Letermovir for Cytomegalovirus Prevention in Patients Undergoing Hematopoietic Cell Transplantation
Cytomegalovirus (CMV) is a double-stranded DNA virus that infects (seropositive on screening) more than half of adults by age 40. However, reactivation of detectable viral load (CMV reactivation) typically occurs only in immunocompromised patients. Notably, CMV reactivation after allogeneic hematopoietic cell transplant (HCT) can increase treatment-related mortality almost 2-fold compared to patients who do not have reactivation. Historically, prevention of CMV reactivation mainly included the preemptive strategy of serial monitoring of viral load and initiating an antiviral once the viral load became elevated in an effort to prevent end-organ disease. The major limitations of the antiviral agents utilized in preemptive therapy are myelosuppression and renal toxicity. In 2017, a first-in-class viral terminase complex subunit inhibitor, letermovir, became the only U.S. Food & Drug Administration–approved medication to prevent CMV reactivation after allogeneic HCT (e.g., as prophylaxis). In a phase III trial, patients who were randomized to letermovir prophylactically had decreased rates of CMV viremia leading to preemptive therapy. The purpose of this article is to describe the need for safe and effective medication to prevent CMV reactivation, the clinical efficacy of letermovir, and the impact oncology advanced practitioners can play in reducing CMV reactivation in patients undergoing allogeneic HCT.
- 1 October 2019
- Published by Harborside Press, LLC in Journal of the Advanced Practitioner in Oncology
- Vol. 10 (7) , 730-735
Letermovir for Cytomegalovirus Prevention in Patients Undergoing Hematopoietic Cell Transplantation
Cytomegalovirus (CMV) is a double-stranded DNA virus that infects (seropositive on screening) more than half of adults by age 40. However, reactivation of detectable viral load (CMV reactivation) typically occurs only in immunocompromised patients. Notably, CMV reactivation after allogeneic hematopoietic cell transplant (HCT) can increase treatment-related mortality almost 2-fold compared to patients who do not have reactivation. Historically, prevention of CMV reactivation mainly included the preemptive strategy of serial monitoring of viral load and initiating an antiviral once the viral load became elevated in an effort to prevent end-organ disease. The major limitations of the antiviral agents utilized in preemptive therapy are myelosuppression and renal toxicity. In 2017, a first-in-class viral terminase complex subunit inhibitor, letermovir, became the only U.S. Food & Drug Administration–approved medication to prevent CMV reactivation after allogeneic HCT (e.g., as prophylaxis). In a phase III trial, patients who were randomized to letermovir prophylactically had decreased rates of CMV viremia leading to preemptive therapy. The purpose of this article is to describe the need for safe and effective medication to prevent CMV reactivation, the clinical efficacy of letermovir, and the impact oncology advanced practitioners can play in reducing CMV reactivation in patients undergoing allogeneic HCT.